184 related articles for article (PubMed ID: 35068071)
1. Bortezomib-Encapsulated Dual Responsive Copolymeric Nanoparticles for Gallbladder Cancer Targeted Therapy.
Chen M; Juengpanich S; Li S; Topatana W; Lu Z; Zheng Q; Cao J; Hu J; Chan E; Hou L; Chen J; Chen F; Liu Y; Jiansirisomboon S; Gu Z; Tongpeng S; Cai X
Adv Sci (Weinh); 2022 Mar; 9(7):e2103895. PubMed ID: 35068071
[TBL] [Abstract][Full Text] [Related]
2. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
[TBL] [Abstract][Full Text] [Related]
3. Adavosertib-encapsulated metal-organic frameworks for p53-mutated gallbladder cancer treatment via synthetic lethality.
Li S; Juengpanich S; Topatana W; Xie T; Hou L; Zhu Y; Chen J; Shan Y; Han Y; Lu Z; Chen T; Topatana C; Zhang B; Cao J; Hu J; Yan J; Chen Y; Gu Z; Yu J; Cai X; Chen M
Sci Bull (Beijing); 2024 May; 69(9):1286-1301. PubMed ID: 38519399
[TBL] [Abstract][Full Text] [Related]
4. Smart pH-responsive polyhydralazine/bortezomib nanoparticles for remodeling tumor microenvironment and enhancing chemotherapy.
Wang R; Xu X; Li D; Zhang W; Shi X; Xu H; Hong J; Yao S; Liu J; Wei Z; Piao Y; Zhou Z; Shen Y; Tang J
Biomaterials; 2022 Sep; 288():121737. PubMed ID: 36031455
[TBL] [Abstract][Full Text] [Related]
5. BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma.
Dutta D; Liu J; Wen K; Kurata K; Fulciniti M; Gulla A; Hideshima T; Anderson KC
Blood Cancer J; 2023 Dec; 13(1):184. PubMed ID: 38072962
[TBL] [Abstract][Full Text] [Related]
6. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
[TBL] [Abstract][Full Text] [Related]
7. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.
Hideshima T; Qi J; Paranal RM; Tang W; Greenberg E; West N; Colling ME; Estiu G; Mazitschek R; Perry JA; Ohguchi H; Cottini F; Mimura N; Görgün G; Tai YT; Richardson PG; Carrasco RD; Wiest O; Schreiber SL; Anderson KC; Bradner JE
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13162-13167. PubMed ID: 27799547
[TBL] [Abstract][Full Text] [Related]
8. Bone-Targeted Bortezomib Inhibits Bortezomib-Resistant Multiple Myeloma in Mice by Providing Higher Levels of Bortezomib in Bone.
Tao J; Srinivasan V; Yi X; Zhao Y; Zhang H; Lin X; Zhou X; Boyce BF; Villalta PW; Ebetino FH; Ho KK; Boeckman RK; Xing L
J Bone Miner Res; 2022 Apr; 37(4):629-642. PubMed ID: 34970782
[TBL] [Abstract][Full Text] [Related]
9. Multifunctional Telodendrimer Nanocarriers Restore Synergy of Bortezomib and Doxorubicin in Ovarian Cancer Treatment.
Wang L; Shi C; Wright FA; Guo D; Wang X; Wang D; Wojcikiewicz RJH; Luo J
Cancer Res; 2017 Jun; 77(12):3293-3305. PubMed ID: 28396359
[TBL] [Abstract][Full Text] [Related]
10. Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations.
Liu J; Zhao R; Jiang X; Li Z; Zhang B
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053199
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
12.
Rani S; Sahoo RK; Kumar V; Chaurasiya A; Kulkarni O; Mahale A; Katke S; Kuche K; Yadav V; Jain S; Nakhate KT; Ajazuddin ; Gupta U
Mol Pharm; 2023 Jan; 20(1):524-544. PubMed ID: 36306447
[TBL] [Abstract][Full Text] [Related]
13. Utilization of Lipid-based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib.
Korani M; Korani S; Zendehdel E; Jaafari MR; Sathyapalan T; Sahebkar A
Anticancer Agents Med Chem; 2020; 20(6):643-650. PubMed ID: 31985384
[TBL] [Abstract][Full Text] [Related]
14. Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance.
Dolloff NG
Adv Cancer Res; 2015; 127():191-226. PubMed ID: 26093901
[TBL] [Abstract][Full Text] [Related]
15. Histone H2A-peptide-hybrided upconversion mesoporous silica nanoparticles for bortezomib/p53 delivery and apoptosis induction.
Rong J; Li P; Ge Y; Chen H; Wu J; Zhang R; Lao J; Lou D; Zhang Y
Colloids Surf B Biointerfaces; 2020 Feb; 186():110674. PubMed ID: 31855686
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin Disrupts Proteasome Bounce-Back Effect through Suppressing ZEB1/Nfe2l1 in Cholangiocarcinoma.
Xiang Y; Jia M; Gao Y; Yang F; Wang T; Dai R; Wang M; Miao H
Front Biosci (Landmark Ed); 2024 Mar; 29(3):106. PubMed ID: 38538281
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics.
Mahmoudian M; Valizadeh H; Löbenberg R; Zakeri-Milani P
J Microencapsul; 2021 May; 38(3):192-202. PubMed ID: 33530812
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma.
Marino S; Petrusca DN; Bishop RT; Anderson JL; Sabol HM; Ashby C; Layer JH; Cesarano A; Davé UP; Perna F; Delgado-Calle J; Chirgwin JM; Roodman GD
Haematologica; 2024 May; 109(5):1501-1513. PubMed ID: 37981834
[TBL] [Abstract][Full Text] [Related]
20. Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.
de la Puente P; Luderer MJ; Federico C; Jin A; Gilson RC; Egbulefu C; Alhallak K; Shah S; Muz B; Sun J; King J; Kohnen D; Salama NN; Achilefu S; Vij R; Azab AK
J Control Release; 2018 Jan; 270():158-176. PubMed ID: 29196043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
